Quick Answer
Aspira Women's Health Inc. reported Research And Development Expense of $3.27 million for the year ending 2024.
- Aspira Women's Health Inc. showed a decrease of -19.1% in Research And Development Expense from 2023 to 2024.
- This data is from Aspira Women's Health Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
- XBRL data for this metric is available from 2010 to 2024 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2010 to 2024), Aspira Women's Health Inc.'s Research And Development Expense has declined by 15.1%.
- Historical annual values: Fiscal year 2024: $3.27 million | Fiscal year 2023: $4.04 million | Fiscal year 2022: $5.92 million | Fiscal year 2021: $5.31 million | Fiscal year 2020: $2.10 million | Fiscal year 2019: $1.02 million | Fiscal year 2018: $550.0 thousand | Fiscal year 2017: $837.0 thousand | Fiscal year 2016: $2.17 million | Fiscal year 2015: $3.75 million | Fiscal year 2014: $4.67 million | Fiscal year 2013: $2.60 million | Fiscal year 2012: $2.22 million | Fiscal year 2011: $5.39 million | Fiscal year 2010: $3.85 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: